Myelodysplastic Syndrome / Secondary Acute Myeloid Leukemia: role of the allogeneic hematopoietic stem cell transplantation

Authors

  • Yhasmine Delles Oliveira Garcia Discente Programa de Pós-Graduação em Ciências Farmacêuticas da Universidade Federal do Ceará. Fortaleza, Ceará, Brasil
  • Juliene Lima Mesquita 1Discente Programa de Pós-Graduação em Ciências Farmacêuticas da Universidade Federal do Ceará. Fortaleza, Ceará, Brasil.
  • Yensy Mariana Zelaya Rosales Discente Programa de Pós-Graduação em Ciências Farmacêuticas da Universidade Federal do Ceará. Fortaleza, Ceará, Brasil
  • Anna Thawanny Gadelha Moura Discente Programa de Pós-Graduação em Ciências Farmacêuticas da Universidade Federal do Ceará. Fortaleza, Ceará, Brasil
  • Beatriz Stela Gomes de Sousa Pitombeira Araujo Médico (a) do serviço de Hematologia do Hospital Universitário Walter Cantídio, Fortaleza, Ceará. Brasil
  • João Paulo de Vasconcelos Leitão Médico (a) do serviço de Hematologia do Hospital Universitário Walter Cantídio, Fortaleza, Ceará. Brasil
  • Karine Sampaio Nunes Barroso Médico (a) do serviço de Hematologia do Hospital Universitário Walter Cantídio, Fortaleza, Ceará. Brasil
  • Lívia Andrade Gurgel Médico (a) do serviço de Hematologia do Hospital Universitário Walter Cantídio, Fortaleza, Ceará. Brasil
  • Francisco Dario Rocha Filho Centro de Análises Clínicas (CAC) – Fortaleza (CE), Brasil
  • João Vitor Araújo Duarte Aluno do Centro Universitário Christus-Fortaleza (CE), Brazil
  • Isabella Araújo Duarte Aluno do Centro Universitário Christus-Fortaleza (CE), Brazil
  • Beatrice Araújo Duarte Aluno do Centro Universitário Christus-Fortaleza (CE), Brazil
  • Romélia Pinheiro Gonçalves Lemes Professora Titular do Departamento de Análises Clínicas da Faculdade de Farmácia da Universidade Federal do Ceará. Fortaleza, Ceará, Brasil
  • Fernando Barroso Duarte Centro de Análises Clínicas (CAC) – Fortaleza (CE), Brasil; Professor Adjunto do Departamento de Cirurgia e Chefe do Serviço de Transplante de Medula Óssea da Universidade Federal do Ceará. Fortaleza, Ceará, Brasil

DOI:

https://doi.org/10.46765/2675-374X.2020v1n1p15-18

Keywords:

Secondary Myeloid Leukemia, Myelodysplastic Syndrome, Autologous Hematopoietic Stem Cell Transplantation, Relapse, Diagnosis

Abstract

Secondary Acute Myeloid Leukemia (s-AML) refers to the development of leukemia after cytotoxic therapy, immunosuppressive therapy, radiation or an antecedent hematological disorder, such as Myelodysplastic Syndrome (MDS). A s-AML corresponds to 10% to 30% of AML cases and is defined by the presence of at least 20% of blast cells, representing a category of disease with a poor prognosis. Allogeneic hematopoietic stem cell transplan­tation (Allo-HSCT) is the only option with curative potential for patients with s-AML, but recurrence after HSCT emerges as a frequent cause of treatment failure and course with high mortality. We report the case of a patient with s-AML after MDS, who underwent HSCT due to refractoriness to other treatments, recovering the bone marrow with dysplasia, be­ing classified as AREB1.

Downloads

Published

07/06/2020

How to Cite

Garcia, Y. D. O., Mesquita, J. L., Rosales, Y. M. Z., Moura, A. T. G., Araujo, B. S. G. de S. P., Leitão, J. P. de V., Barroso, K. S. N., Gurgel, L. A., Filho, F. D. R., Duarte, J. V. A., Duarte, I. A., Duarte, B. A., Lemes, R. P. G., & Duarte, F. B. (2020). Myelodysplastic Syndrome / Secondary Acute Myeloid Leukemia: role of the allogeneic hematopoietic stem cell transplantation. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(2), 15–18. https://doi.org/10.46765/2675-374X.2020v1n1p15-18

Issue

Vol. 1 No. 2 (2020): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

License

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)

1 2 3 > >> 

Similar Articles

You may also start an advanced similarity search for this article.